Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

14-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Additional data from the EV-103 trial

Jonathan Rosenberg provides an update on the EV-103 trial of combined enfortumab vedotin plus pembrolizumab for the first-line treatment of cisplatin-ineligible advanced urothelial carcinoma (3:40).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

20-12-2019 | FDA | News

Enzalutamide, enfortumab vedotin-ejfv receive FDA nods

16-10-2019 | Urothelial cancer | Conference coverage | News

​​​​​​​Enfortumab vedotin–pembrolizumab duo has potential in urothelial carcinoma

12-06-2019 | Urothelial cancer | Video | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

12-06-2019 | Urothelial cancer | Video | Article

Researcher comment: Enfortumab vedotin active in advanced urothelial carcinoma
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

ASCO GU 2020 conference hub

ASCO GU 2020 conference hub

Access all the latest news and expert video commentary from the 2020 Genitourinary Cancers Symposium in San Francisco, USA.

Register for conference alerts

Receive the latest content direct to your inbox.

Image Credits